These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12914137)

  • 21. [Let "Svensson" decide about his health care. Insurance instead of power of politicians].
    Persson B
    Lakartidningen; 1993 Mar; 90(11):1022. PubMed ID: 8464282
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Waiting lists for surgery are expensive--depending on how we calculate. No calculation method is without controversies].
    Norlund A
    Lakartidningen; 2003 Apr; 100(16):1416-8. PubMed ID: 12756708
    [No Abstract]   [Full Text] [Related]  

  • 25. Guidelines--are they useful?
    Ben-Menachem E; French JA
    Epilepsia; 2006; 47 Suppl 1():62-4. PubMed ID: 17044829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new approach to decision making for health care managers.
    Krasny J
    Health Manage Forum; 1980; 1(1):71-87. PubMed ID: 10309272
    [No Abstract]   [Full Text] [Related]  

  • 27. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug committees are not necessary--therapeutic recommendations are issued anyway].
    Jönsson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181
    [No Abstract]   [Full Text] [Related]  

  • 29. Criteria and procedures for determining benefit packages in health care. A comparative perspective.
    Gress S; Niebuhr D; Rothgang H; Wasem J
    Health Policy; 2005 Jul; 73(1):78-91. PubMed ID: 15911059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to value-based insurance design.
    Kelly AM; Cronin P; Carlos RC
    J Am Coll Radiol; 2008 Nov; 5(11):1118-24. PubMed ID: 18954811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 32. From European to national guidelines on heart disease.
    Grip L; Lindahl B; Levin LÅ; Kärvinge C; Eklund K; Wallentin L
    Scand Cardiovasc J; 2011 Feb; 45(1):3-13. PubMed ID: 21133643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug utilization decisions should be based on cost-benefit data].
    Bengt J; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Apr 18-24; 102(16):1264-5; discussion 1265. PubMed ID: 15921102
    [No Abstract]   [Full Text] [Related]  

  • 34. [Should physicians prioritize according to costs or benefits?].
    Sagsveen M; Rørtveit G
    Tidsskr Nor Laegeforen; 2010 Mar; 130(6):588. PubMed ID: 20348988
    [No Abstract]   [Full Text] [Related]  

  • 35. Value for money in changing clinical practice: should decisions about guidelines and implementation strategies be made sequentially or simultaneously?
    Hoomans T; Severens JL; Evers SM; Ament AJ
    Med Decis Making; 2009; 29(2):207-16. PubMed ID: 19237645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness.
    Jansson S; Anell A
    Health Policy; 2006 May; 76(3):299-311. PubMed ID: 16046026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inspra and the drug benefits board: What is the role of the drug committees?].
    Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183
    [No Abstract]   [Full Text] [Related]  

  • 38. Attitudes towards priority-setting and rationing in healthcare -- an exploratory survey of Swedish medical students.
    Omar F; Tinghög G; Tinghög P; Carlsson P
    Scand J Public Health; 2009 Mar; 37(2):122-30. PubMed ID: 19141543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Health services need knowledge of how the public values health].
    Persson U; Hjelmgren J
    Lakartidningen; 2003 Oct; 100(43):3436-7. PubMed ID: 14626774
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.